Letrozole in Tubal Ectopic Pregnancy

Tubal Pregnancy Clinical Trial

Official title:

Randomized Controlled Trial on Use of Letrozole in the Medical Management of Tubal Ectopic Pregnancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04341545
• Other study ID #: UW 20-005
• Status: Recruiting
• Phase: Phase 3
• Start date: December 1, 2020
• Est. completion date: March 31, 2025

Study information

• Verified date: April 2023
• Source: Queen Mary Hospital, Hong Kong
• Contact: Evelyn Wong, MBBS
• Phone: 22554517
• Email: evelynwong.ew[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-centred randomized controlled trial on the addition of letrozole in the medical management of tubal ectopic pregnancies.

Tubal ectopic pregnancies are abnormal pregnancies in the Fallopian tube, rather than in the womb. They occurred in around 1-2% of all pregnancies. Methotrexate (MTX) given by the intramuscular route i.e. systemic, a commonly used drug for cancer , was a widely used alternative for management for unruptured tubal ectopic pregnancies and was recommended as first line treatment for selected women.

Letrozole, aromatase inhibitor, can suppose oestradiol level. Combination of letrozole with misprostol has shown to improve the complete abortion rate in miscarriage. As a result, addition of letrozole may cause a higher success rate in the medical treatment of ectopic pregnancy.

As the evidence of combination of MTX and letrozole in tubal ectopic pregnancies is not available, the objective of the present study is to evaluate the efficacy of combination of MTX and letrozole compared to MTX alone in women with tubal ectopic pregnancies.

Description:

Tubal ectopic pregnancies occur in around 1-2% of all pregnancies. Traditionally, surgery with salpingectomy was the mainstay of treatment; however, it comes with anaesthetic and operatives risks in addition to an increased cost for operative procedures. In recent years, systemic methotrexate (MTX), a dihydrofolate reductase inhibitor, has been a widely used alternative for management for unruptured tubal ectopic pregnancies. The success rate of systemic MTX at a doses of 50mg/m2 body surface area is around 70% which ranges from 65 to 95%, depending greatly on the level of human chorionic gonadotrophin (hCG), the size of adnexal mass and presence of fetal heart pulsation.

Use of systemic MTX as the first-line management has been proposed for women with unruptured ectopic pregnancy where the adnexal mass is smaller than 35mm, serum hCG level is less than 5000 IU/l and fetal heartbeat is absent.

Letrozole is a third generation non-steroidal reversible aromatase inhibitor. It can suppress oestradiol level up to 95% to 99% after administration according to pharmacodynamics and pharmacokinetics studies. Oestrogen is important in the support of early pregnancy, other than progesterone with well-known pivotal effect on the maintenance of early pregnancy.

Animal studies showed the combination of mifepristone and letrozole worked synergistically and induced almost 100% termination of pregnancies in rats. Letrozole induced 50% miscarriage rate in pregnant baboons. Letrozole combined with vaginal misoprostol regimen was associated with a higher complete abortion rate than misoprostol alone in pregnancies up to 63 days.

The use of letrozole in ectopic pregnancy has never been explored. It is hypothesized that letrozole can suppress serum oestradiol level, which in turn, may cause failure of pregnancy in ectopic pregnancy. The aim of this study is to investigate the clinical effectiveness of letrozole in addition to MTX in the medical treatment of ectopic pregnancy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 214
• Est. completion date: March 31, 2025
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Presence of heterogenous adnexal mass on USG suggestive of tubal ectopic pregnancy with hCG level >=1500 IU/L and <= 5000 IU/L

• Absence of fetal heart pulsation

• Mean diameter of adnexal mass <= 3.5cm

• Haemodynamically stable

• No significant abdominal pain

Exclusion Criteria:

• Presence of significant amount of free fluid in pelvis

• Allergic to MTX

• Deranged liver function test (AST/ ALT or GGT >= 2 upper limit of normal)

• Deranged renal function test (eGFR <= 45ml/min)

• Heterotopic pregnancies

Related Conditions & MeSH terms

• Pregnancy, Ectopic
• Tubal Pregnancy

Intervention

Other:
• Placebos
Placebo 4 tablets a day for one week.

Drug:
• Letrozole tablets
Letrozole 10mg daily for one week.

Locations

Country	Name	City	State
Hong Kong	Department of Obstetrics and Gynaecology, Queen Mary Hospital	Hong Kong

Sponsors (6)

Lead Sponsor	Collaborator
Queen Mary Hospital, Hong Kong	Kwong Wah Hospital, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, Princess Margaret Hospital, Hong Kong, Queen Elizabeth Hospital, Hong Kong

Country where clinical trial is conducted

Hong Kong, 

References & Publications (8)

Albrecht ED, Aberdeen GW, Pepe GJ. The role of estrogen in the maintenance of primate pregnancy. Am J Obstet Gynecol. 2000 Feb;182(2):432-8. doi: 10.1016/s0002-9378(00)70235-3. — View Citation

Diagnosis and Management of Ectopic Pregnancy: Green-top Guideline No. 21. BJOG. 2016 Dec;123(13):e15-e55. doi: 10.1111/1471-0528.14189. Epub 2016 Nov 3. No abstract available. Erratum In: BJOG. 2017 Dec;124(13):e314. — View Citation

Lee VC, Tang OS, Ng EH, Yeung WS, Ho PC. A pilot study on the use of letrozole with either misoprostol or mifepristone for termination of pregnancy up to 63 days. Contraception. 2011 Jan;83(1):62-7. doi: 10.1016/j.contraception.2010.05.014. Epub 2010 Jun 23. — View Citation

Lee VCY, Ng EHY, Yeung WSB, Ho PC. Misoprostol with or without letrozole pretreatment for termination of pregnancy: a randomized controlled trial. Obstet Gynecol. 2011 Feb;117(2 Pt 1):317-323. doi: 10.1097/AOG.0b013e3182073fbf. — View Citation

National Collaborating Centre for Ws, Children's H. National Institute for Health and Clinical Excellence: Guidance. Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management in Early Pregnancy of Ectopic Pregnancy and Miscarriage. London: Rcog National Collaborating Centre for Women's and Children's Health.; 2012.

Odejinmi F, Huff KO, Oliver R. Individualisation of intervention for tubal ectopic pregnancy: historical perspectives and the modern evidence based management of ectopic pregnancy. Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:69-75. doi: 10.1016/j.ejogrb.2016.10.037. Epub 2016 Oct 29. — View Citation

Panelli DM, Phillips CH, Brady PC. Incidence, diagnosis and management of tubal and nontubal ectopic pregnancies: a review. Fertil Res Pract. 2015 Oct 15;1:15. doi: 10.1186/s40738-015-0008-z. eCollection 2015. — View Citation

Shi L, Shi SQ, Given RL, von Hertzen H, Garfield RE. Synergistic effects of antiprogestins and iNOS or aromatase inhibitors on establishment and maintenance of pregnancy. Steroids. 2003 Nov;68(10-13):1077-84. doi: 10.1016/j.steroids.2003.09.002. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment success	Proportion of women with treatment success defined as normalization of serum hCG level <10IU/L without additional medical or surgical intervention	2 months
Secondary	hCG normalization duration	Duration of time until hCG normalization measured in days	2 months
Secondary	Number of participants experienced side effects	Side effects after letrozole	2 months
Secondary	Duration of hospitalization	Duration of hospitalization	2 months
Secondary	Participant satisfaction: proportion of women who would recommend this treatment to a friend	Treatment satisfaction measured as proportion of women who would recommend this treatment to a friend	2 months